Jennifer Silvent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jennifer silvent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jennifer Silvent Today - Breaking & Trending Today

Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the primary results from the Phase 1/2 study evaluating the. ....

United Kingdom , United States , Clin Chim Acta , Michel Michaelides , Botaretigene Sparoparvovec , Jennifer Silvent , None Of The Janssen Pharmaceutical Companies , University College London , Drug Administration , American Academy Of Ophthalmology , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , American Academy Of Ophthalmology Annual Meeting , Meiragtx Holdings , Companies Of Johnson , European Medicines Agency , Retina Subspecialty Day , American Academy , Multichannel News Release , Consultant Ophthalmologist , Moorfields Eye Hospital , Fast Track , Orphan Drug , Advanced Therapy Medicinal Product ,

Johnson & Johnson : FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD

Johnson & Johnson : FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Ryan Gough , Marcp Bonaca , Jennifer Mcintyre , Lee Pasqualoni , Traciec Collins , Winta Ghidei , Jennifer Silvent , American Heart Association , Division Of Cardiovascular Medicine , Janssen Pharmaceuticals Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Clinical Research , Partnership To Advance Cardiovascular Health , Department Of Medicine , None Of The Janssen Pharmaceutical Companies , International Scholarly Research Notices , University Of Colorado Anschutz Medical Campus , Drug Administration , Exchange Commission , Companies Of Johnson , Cardiovascular Medicine , Colorado Anschutz Medical Campus , Executive Director ,

Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization

Share this article
Share this article
RARITAN, N.J., May 16, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO
® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO
® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiolo ....

United States , Marcp Bonaca , Jennifer Mcintyre , Lee Pasqualoni , Christopher Delorefice , Jennifer Silvent , American Heart Association , Division Of Cardiovascular Medicine , Janssen Pharmaceuticals Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Journal Of The American College Cardiology , Clinical Research , Department Of Medicine , None Of The Janssen Pharmaceutical Companies , University Of Colorado Anschutz Medical Campus , American College Of Cardiology , Drug Administration , Exchange Commission , Companies Of Johnson , American College , Annual Scientific Session , Cardiovascular Medicine , Colorado Anschutz Medical Campus , Hazard Ratio ,